Lupin Limited - Asset Resilience Ratio
Lupin Limited (LUPIN) has an Asset Resilience Ratio of 18.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LUPIN strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Lupin Limited's Asset Resilience Ratio has changed over time. See LUPIN equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lupin Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Lupin Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs30.40 Billion | 9.08% |
| Short-term Investments | Rs32.42 Billion | 9.68% |
| Total Liquid Assets | Rs62.82 Billion | 18.75% |
Asset Resilience Insights
- Good Liquidity Position: Lupin Limited maintains a healthy 18.75% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Lupin Limited Industry Peers by Asset Resilience Ratio
Compare Lupin Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
Annual Asset Resilience Ratio for Lupin Limited (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Lupin Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.95% | Rs14.46 Billion ≈ $156.40 Million |
Rs292.05 Billion ≈ $3.16 Billion |
+0.82pp |
| 2024-03-31 | 4.13% | Rs9.91 Billion ≈ $107.17 Million |
Rs239.97 Billion ≈ $2.60 Billion |
+1.19pp |
| 2023-03-31 | 2.94% | Rs6.74 Billion ≈ $72.92 Million |
Rs229.56 Billion ≈ $2.48 Billion |
-1.71pp |
| 2022-03-31 | 4.65% | Rs10.14 Billion ≈ $109.70 Million |
Rs218.21 Billion ≈ $2.36 Billion |
-5.77pp |
| 2021-03-31 | 10.42% | Rs24.59 Billion ≈ $265.98 Million |
Rs236.10 Billion ≈ $2.55 Billion |
+0.64pp |
| 2020-03-31 | 9.78% | Rs24.43 Billion ≈ $264.16 Million |
Rs249.84 Billion ≈ $2.70 Billion |
+2.08pp |
| 2019-03-31 | 7.69% | Rs21.51 Billion ≈ $232.57 Million |
Rs279.49 Billion ≈ $3.02 Billion |
+6.50pp |
| 2018-03-31 | 1.20% | Rs3.15 Billion ≈ $34.03 Million |
Rs263.05 Billion ≈ $2.84 Billion |
-6.92pp |
| 2017-03-31 | 8.11% | Rs21.59 Billion ≈ $233.50 Million |
Rs266.07 Billion ≈ $2.88 Billion |
+8.06pp |
| 2016-03-31 | 0.05% | Rs120.20 Million ≈ $1.30 Million |
Rs226.25 Billion ≈ $2.45 Billion |
-12.55pp |
| 2015-03-31 | 12.60% | Rs16.56 Billion ≈ $179.08 Million |
Rs131.38 Billion ≈ $1.42 Billion |
+10.88pp |
| 2014-03-31 | 1.73% | Rs1.76 Billion ≈ $19.08 Million |
Rs102.06 Billion ≈ $1.10 Billion |
+1.73pp |
| 2012-03-31 | 0.00% | Rs1.50 Million ≈ $16.22K |
Rs79.82 Billion ≈ $863.25 Million |
-- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more